Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Rooyakkers A, Ye L, Cahn PE, Ruiz-Palacios GM, Ikram A, Lanas F, Navarro SRM, Sued O, Lioznov DA, Dzutseva V, Parveen G, Zubkova T, Li J, Langley JM, Wang R, Barreto L, Gou J, Zhu T, Whittle CA, Halperin SA, CanSino COVID-19 Global Efficacy Study Group

Open source

DOI: 10.1016/j.vaccine.2026.128424
Published: 2026 Apr 19
Container: Vaccine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.vaccine.2026.128424,
  title = {Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.},
  author = {Rooyakkers A and Ye L and Cahn PE and Ruiz-Palacios GM and Ikram A and Lanas F and Navarro SRM and Sued O and Lioznov DA and Dzutseva V and Parveen G and Zubkova T and Li J and Langley JM and Wang R and Barreto L and Gou J and Zhu T and Whittle CA and Halperin SA and CanSino COVID-19 Global Efficacy Study Group},
  year = {2026},
  journal = {Vaccine},
  doi = {10.1016/j.vaccine.2026.128424},
  url = {https://doi.org/10.1016/j.vaccine.2026.128424}
}

RIS

TY  - JOUR
TI  - Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.
AU  - Rooyakkers A
AU  - Ye L
AU  - Cahn PE
AU  - Ruiz-Palacios GM
AU  - Ikram A
AU  - Lanas F
AU  - Navarro SRM
AU  - Sued O
AU  - Lioznov DA
AU  - Dzutseva V
AU  - Parveen G
AU  - Zubkova T
AU  - Li J
AU  - Langley JM
AU  - Wang R
AU  - Barreto L
AU  - Gou J
AU  - Zhu T
AU  - Whittle CA
AU  - Halperin SA
AU  - CanSino COVID-19 Global Efficacy Study Group
PY  - 2026
JO  - Vaccine
DO  - 10.1016/j.vaccine.2026.128424
UR  - https://doi.org/10.1016/j.vaccine.2026.128424
ER  -

APA

A, R., L, Y., PE, C., GM, R., A, I., F, L., SRM, N., O, S., DA, L., V, D., G, P., T, Z., J, L., JM, L., R, W., L, B., J, G., T, Z., CA, W., SA, H., & Group, C. C. G. E. S. (2026). Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128424

Source records

pubmed · retrieved 2026-09-26T10:43:16.974Z